Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer

The limited treatment options and therapeutic failure due to acquired resistance for patients with triple-negative breast cancer (TNBC) represent a significant challenge. Inhibitors against poly (ADP-ribose) polymerase (PARP), olaparib and talazoparib, were recently approved for the treatment of met...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Am J Cancer Res
Main Authors: Chu, Yu-Yi, Yam, Clinton, Chen, Mei-Kuang, Chan, Li-Chuan, Xiao, Min, Wei, Yong-Kun, Yamaguchi, Hirohito, Lee, Pei-Chih, Han, Ye, Nie, Lei, Sun, Xian, Moulder, Stacy L, Hess, Kenneth R, Wang, Bin, Hsu, Jennifer L, Hortobagyi, Gabriel N, Litton, Jennifer, Chang, Jeffrey T, Hung, Mien-Chie
Formato: Artigo
Idioma:Inglês
Publicado: e-Century Publishing Corporation 2020
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7061756/
https://ncbi.nlm.nih.gov/pubmed/32195033
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares